Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma
Author(s) -
Cathia Soulié,
Maxime Grudé,
Diane Descamps,
Corinne Amiel,
Laurence MorandJoubert,
Stéphanie Raymond,
Coralie Pallier,
Pantxika Bellecave,
Sandrine Reigadas,
MaryAnne Trabaud,
Constance Delaugerre,
Brigitte Montès,
Francis Barin,
Virginie Ferré,
Hélène Jeulin,
Chakib Alloui,
Sabine Yerly,
Anne Signori-Schmück,
Aurélie Guigon,
Samira FafiKremer,
Stéphanie HaïmBoukobza,
Audrey Mirand,
Anne Maillard,
Sophie Vallet,
Catherine Roussel,
Lambert Assoumou,
Vincent Cálvez,
Philippe Flandre,
AnneGeneviève Marcelin
Publication year - 2017
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkx128
Subject(s) - viral load , medicine , genotype , lentivirus , sida , virology , human immunodeficiency virus (hiv) , population , antiretroviral therapy , immunology , viral disease , gastroenterology , biology , biochemistry , environmental health , gene
HIV therapy reduces the CSF HIV RNA viral load (VL) and prevents disorders related to HIV encephalitis. However, these brain disorders may persist in some cases. A large population of antiretroviral-treated patients who had a VL > 1.7 log 10 copies/mL in CSF with detectable or undetectable VL in plasma associated with cognitive impairment was studied, in order to characterize discriminatory factors of these two patient populations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom